TheraRadar
Clinical-Stage Companies / RVL

RVL

Pre-Approval PRO BETA
10
Total Trials
9
Phase 3
1
Phase 2
0
Recruiting
151
Score

Pipeline by Phase

Phase 3
9
Phase 2
1
Phase 1
1

Therapeutic Focus

Multiple Sclerosis Spasticity Blepharoptosis Spasticity, Muscle Sperm

Clinical Trials (10)

NCT05179577 Phase 3 NOT YET RECRUITING

A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Started: 1/1/2027

NCT03319732 Phase 3 COMPLETED

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

Started: 4/3/2018

NCT03290131 Phase 3 COMPLETED

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS

Started: 1/28/2018

NCT02869425 Phase 3 WITHDRAWN

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Started: 7/1/2016

NCT01743651 Phase 3 COMPLETED

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Started: 11/1/2012

NCT01844232 Phase 3 COMPLETED

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Started: 4/1/2013

NCT02436759 Phase 3 COMPLETED

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Started: 5/1/2015

NCT03536949 Phase 3 COMPLETED

Study of Safety of RVL-1201 in Treatment of Blepharoptosis

Started: 6/20/2018

NCT03565887 Phase 3 COMPLETED

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

Started: 6/28/2018

NCT01848041 Phase 1 COMPLETED

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

Started: 5/1/2013

Drug Candidates

Arbaclofen Placebo arbaclofen ER Tablets Placebo for arbaclofen ER tablets arbaclofen baclofen RVL-1201 RVL-1201 Vehicle Placebo
Activity Status: Active
Last Trial Started: 1/1/2027
Last Trial Ended: 6/11/2020
Trials (12 months): 1
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.